April 29, 2025
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies
Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns
FDA approves Abeonas skin disease cell therapy
ZEVASKYN, United States Food and Drug Administration, Hallopeau-Siemens Disease, Approved, Wounds – qualifier, gene therapy, Abeona, Treating
Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027
Financial savings, Pfizer, Financial cost, Pfizer
Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions
Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges
HHS lifts stop work order on Vaxart’s COVID-19 trial, continues funding for the 10,000-participant study
Vaxart, COVID-19 vaccine, oral pill vaccine, stop work order lifted, BARDA funding, 10, 000-participant study, Phase 2b trial, next-generation COVID vaccine
Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M
Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes
France pauses chikungunya vaccinations in the elderly after patient death
Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination
AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer
Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability